🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

iRegene Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with iRegene Therapeutics as lead sponsor. Synced 26 Sep 2026
6Current trials
4Recruiting now
0Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

iRegene Therapeutics is the lead sponsor of 6 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 1. The most-studied condition is Parkinson Disease.

ClinicalTrials.gov trials by status

  • Recruiting467%
  • Not yet open233%

Trials by phase

  • Phase 1350%
  • Phase 1/2233%
  • Phase 2117%
01

Clinical trials sponsored by iRegene Therapeutics

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
NCT07102342 · ClinicalTrials.gov ↗ · Parkinson Disease
Phase 1/2 Recruiting 2026-01 USA
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
NCT06167681 · ClinicalTrials.gov ↗ · Parkinson Disease
Phase 1/2 Recruiting 2024-01 China
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
NCT07289477 · ClinicalTrials.gov ↗ · Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Phase 1 Recruiting 2026-01 China
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
NCT06608355 · ClinicalTrials.gov ↗ · Early-onset Parkinson's Disease
Phase 1 Recruiting 2024-08 China
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
NCT07550374 · ClinicalTrials.gov ↗ · Parkinson's Disease (PD)
Phase 1 Not yet open 2026-05 China
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
NCT07028632 · ClinicalTrials.gov ↗ · Parkinson Disease (PD)
Phase 2 Not yet open 2025-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in iRegene Therapeutics trials

5 conditions
Parkinson Disease2Multiple System Atrophy - Parkinsonian Subtype (MSA-P)1Early-onset Parkinson's Disease1Parkinson's Disease (PD)1Parkinson Disease (PD)1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China53
Clinical trials in USA11

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Parkinson Disease

SponsorTrials
Xiangya Hospital of Central South University7
Anhui Medical University4
InSightec2
AskBio1
BlueRock Therapeutics1

Sponsors with the most current trials registered for this condition.

05

Questions about iRegene Therapeutics trials

How many clinical trials does iRegene Therapeutics sponsor?

iRegene Therapeutics is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are iRegene Therapeutics trials recruiting?

Yes. 4 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.